This study, called CORTISHOCK-P, is looking at whether a short course of a steroid medication called methylprednisolone can help patients with heart failure-related cardiogenic shock. Cardiogenic shock happens when your heart can't pump enough blood to your body, often leading to severe inflammation. Researchers want to see if reducing this inflammation with methylprednisolone, given along with your usual medical care, is safe and helps you recover faster. You could be eligible if you are 18-80 years old, in the ICU with cardiogenic shock, and have signs of inflammation. The study will measure changes in a marker of inflammation (hsCRP) to see if the treatment is working. About 30 patients are planned for this study, and its current status is unclear.

Study design

This is a pilot study that will include about 30 participants. It is a randomized, open-label study, meaning participants will be randomly assigned to a treatment group, and both you and your doctors will know which treatment you are receiving.

What's involved

Participants will receive methylprednisolone intravenously for 7 days, starting with 80 mg daily for 3 days, followed by a tapering dose for 4 additional days. You will also receive routine medical care for your condition.

Compensation

Not stated in the trial record.

Follow-up

Your inflammation levels will be measured at baseline, 24, 48, 72, and 96 hours, and at day 7 or when you leave the ICU.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.